Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenACWY-CRM vs MenACWY-PS in Children and Toddlers
NCT00262028Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal A, C, Y and W-135 conjugate vaccine in meningococcal disease (5 arms), sponsored by Novartis. Primary endpoint: Percentage of Subjects with Human Serum Bactericidal Activity (hSBA) Titers >= 1:4. Started Apr 2005; status: completed.
02
Drugs
Meningococcal A, C, Y and W-135 conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00262028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262028.